Sysmex Stock

Sysmex Equity

The The Equity of Sysmex (6869.T) as of Jul 23, 2026 is 463.78 B JPY. In the previous year, The Equity was 432.05 B JPY — a change of 7.34% (higher).

Equity

463.78 BJPY

YoY

7.34%

Last updated:

In 2026, Sysmex's equity was 463.78 B JPY, a 7.34% increase from the 432.05 B JPY equity in the previous year.

Access this data via the Eulerpool API

Sysmex Stock analysis

What does Sysmex do? Sysmex Corp is a Japanese company that has been a leading provider of diagnostic and analytical laboratory systems and solutions for the healthcare industry since its founding in 1968. The company is headquartered in Kobe, Japan and employs over 9,000 people worldwide. History: Sysmex was founded by a group of young scientists in Japan who wanted to develop an automated blood cell analysis system to improve the high workload of manual blood analysis at the time. The company began developing this system and brought it to market in 1972. Business model: Sysmex focuses on the development, production, and sale of diagnostic systems and solutions for medical laboratories around the world. The company specializes in hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology. Divisions: Sysmex Corp is divided into three main business divisions: 1. Diagnostic Systems: This division includes hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology systems. Sysmex is one of the world's leading providers of hematology analysis devices and also offers molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer. 2. Information Solutions: This division offers software and IT solutions that support laboratory management and the integration of laboratory data to optimize analysis processes. The company also offers solutions for automating laboratory processes and managing laboratory inventory. 3. Life Science: This division focuses on the development of products for the life sciences, particularly cell analysis and imaging, as well as production, processing, and storage of cell cultures. Sysmex is also involved in the production of devices for harvesting mesenchymal stem cells from adipose tissue. Products: Sysmex offers a variety of products, including: - Hematology analysis devices for determining blood cell parameters such as RBC, WBC, HGB, HCT, and platelets. - Hemostasis systems for analyzing blood coagulation. - Molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer. - Urinalysis systems for analyzing urine samples for chemical and microscopic parameters. - Immunology analysis devices for determining specific proteins and antibodies in the blood. - Clinical chemistry analysis devices for analyzing chemical parameters in blood samples. - Software and IT solutions for optimizing laboratory processes and management. - Cell analysis and imaging systems for investigating cell morphology and functions. - Devices for harvesting mesenchymal stem cells from adipose tissue. In summary, Sysmex Corp is a global leader in diagnostic and analytical laboratory systems and solutions for the healthcare industry. In its nearly 50-year history, the company has developed and produced a wide range of products that enable laboratories to perform fast and accurate disease diagnosis. The company has also expanded its business into other areas such as information solutions and the life sciences. Sysmex is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Sysmex's Equity

Sysmex's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Sysmex's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Sysmex's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Sysmex's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Sysmex’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Sysmex stock

The Equity of Sysmex is 463.78 B JPY in 2026.

Access this data via the Eulerpool API

Balance Sheet — Sysmex

All Key Metrics — Sysmex